Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cistron Biotechnology Inc.

Division of UCB Group

Latest From Cistron Biotechnology Inc.

Celltech's New Wherewithal

Britain's original biotech company, Celltech Group PLC, has lately made some strategic moves that make it the biggest biotech firm in all of Europe. The firm has been acquiring discovery, regulatory and marketing assets that will, it hopes, allow it to keep more of the value of its own antibody-based products. Celltech was able to do its acquisitions inexpensively, for stock, because the firms it bought were in trouble and poorly valued by the market. Their assets bring Celltech more potential than it has ever had. Big Pharma partnerships are still an option, but not a necessity. Celltech's challenge going forward is to integrate the new businesses, so they work well together. Even analysts clearly bullish on the company acknowledge the difficulty of the tasks awaiting management. Celltech, now in the spotlight as Europe's biggest biotech firm, possesses size and seniority. But neither will make it a market leader. Celltech must now successfully execute on tasks it has never before attempted.
BioPharmaceutical Leadership

Small-Cap Biotech M&A, via the Internet

Robert Naismith, CEO of eMed Securities, a private investment banking firm, has just sold tiny, troubled American biotech firm Cistron to Celltech in the UK--via the Internet. Naismith put a lot of work into building a case that Cistron's science was good, even if its corporate history was less than sterling. Then he e-mailed letters tailored to different types of potential buyers and watched the information he'd posted on his firm's web site get 30,000 hits in the two weeks. EMed intends to keep on leveraging the Internet, not only to promote M&A of small-cap life science companies, but to help those firms attract retail capital. On-line roadshows are on the way, he says.
BioPharmaceutical Strategy

New England Medical Center

In the era of managed care, can even this relatively large medical center afford its own tech transfer operation?
Europe
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • UCB Group
  • Senior Management
  • Isidore S Edelman, PhD, Chmn. & CEO
    Jonathan E Rothschild, CFO
    Richard S Dondero, VP, Operations & Prod. Dev.
  • Contact Info
  • Cistron Biotechnology Inc.
    Phone: (973) 575-1700
    10 Bloomfield Ave.
    Pine Brook, NJ 07058-
    USA
UsernamePublicRestriction

Register